Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Vedolizumab

Brand: Entyvio®
NICE TA: 342
Indication: First, second and third line treatment of moderately to severely active ulcerative colitis (NICE TA342)
Disease category: Gastro-intestinal system
Commissioning responsibility: CCG
PbR excluded: Yes

Background

Vedolizumab is recommended by LMMG as a first, second or third line biologic option for treating moderately to severely active ulcerative colitis if:
• an anti-TNF has failed, cannot be tolerated or is contraindicated.

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Red

Red

Red

Red

Red

Red